<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="available in this article, unless otherwise stated. Abstract Annual seasonal" exact="influenza" post="epidemics of variable severity result in significant morbidity and"/>
 <result pre="(U.S.) and worldwide. In temperate climate countries, including the U.S.," exact="influenza" post="activity peaks during the winter months. Annual influenza vaccination"/>
 <result pre="the U.S., influenza activity peaks during the winter months. Annual" exact="influenza" post="vaccination is recommended for all persons in the U.S."/>
 <result pre="(e.g. young children, elderly). Observational studies have reported effectiveness of" exact="influenza" post="vaccination to reduce the risks of severe disease requiring"/>
 <result pre="hospitalization, intensive care unit admission, and death. A diagnosis of" exact="influenza" post="should be considered in critically ill patients admitted with"/>
 <result pre="such as exacerbation of underlying chronic comorbidities, community-acquired pneumonia, and" exact="respiratory failure" post="during influenza season. Molecular tests are recommended for influenza"/>
 <result pre="of underlying chronic comorbidities, community-acquired pneumonia, and respiratory failure during" exact="influenza" post="season. Molecular tests are recommended for influenza testing of"/>
 <result pre="respiratory failure during influenza season. Molecular tests are recommended for" exact="influenza" post="testing of respiratory specimens in hospitalized patients. Antigen detection"/>
 <result pre="make clinical decisions, and respiratory specimens should be tested for" exact="influenza" post="by molecular assays. Because critically ill patients with lower"/>
 <result pre="ill patients with lower respiratory tract disease may have cleared" exact="influenza" post="virus in the upper respiratory tract, but have prolonged"/>
 <result pre="influenza virus in the upper respiratory tract, but have prolonged" exact="influenza" post="viral replication in the lower respiratory tract, an endotracheal"/>
 <result pre="purposes) should be tested by molecular assay for detection of" exact="influenza" post="viruses. Observational studies have reported that antiviral treatment of"/>
 <result pre="studies have reported that antiviral treatment of critically ill adult" exact="influenza" post="patients with a neuraminidase inhibitor is associated with survival"/>
 <result pre="unless clinically indicated for another reason, such as treatment of" exact="asthma" post="or COPD exacerbation, or septic shock. A number of"/>
 <result pre="Influenza Influenza vaccination Influenza testing Antiviral treatment Background Annual seasonal" exact="influenza" post="epidemics of variable severity result in significant morbidity and"/>
 <result pre="and worldwide [1–3]. In temperate climate countries, including the U.S.," exact="influenza" post="activity peaks during the winter months whereas in tropical"/>
 <result pre="activity peaks during the winter months whereas in tropical regions" exact="influenza" post="activity may be more variable [4–6]. Most persons with"/>
 <result pre="activity may be more variable [4–6]. Most persons with symptomatic" exact="influenza" post="virus infection have self-limited uncomplicated upper respiratory tract illness."/>
 <result pre="during 2010–2016, approximately 8.3% of the U.S. population experienced symptomatic" exact="influenza" post="each year [7]. However, complications may result in severe"/>
 <result pre="medical visits, 140,000–960,000 hospitalizations, and 12,000–79,000 deaths were associated with" exact="influenza" post="each year in the U.S. [8]. Another study estimated"/>
 <result pre="There are an estimated 291,000–646,000 respiratory deaths attributed to seasonal" exact="influenza" post="each year worldwide [2]. Here, we review strategies for"/>
 <result pre="Here, we review strategies for prevention, diagnosis, and treatment of" exact="influenza" post="virus infections in the ICU (Table 1). Table 1"/>
 <result pre="1). Table 1 Key points: care of patients with severe" exact="influenza" post="Key Points • There are an estimated 291,000–646,000 seasonal"/>
 <result pre="291,000–646,000 seasonal influenza-associated respiratory deaths every year worldwide. • Annual" exact="influenza" post="vaccination is the primary method of preventing influenza and"/>
 <result pre="• Annual influenza vaccination is the primary method of preventing" exact="influenza" post="and influenza-related complications, especially in high-risk persons. • Influenza"/>
 <result pre="patients, and should not be delayed while awaiting results of" exact="influenza" post="diagnostic tests. • Enterically administered oseltamivir is recommended for"/>
 <result pre="influenza diagnostic tests. • Enterically administered oseltamivir is recommended for" exact="influenza" post="patients except for those with contraindications (e.g., gastric stasis,"/>
 <result pre="be required to determine therapeutic endpoints in ventilated patients with" exact="influenza" post="• Corticosteroids are not recommended for the routine treatment"/>
 <result pre="• Corticosteroids are not recommended for the routine treatment of" exact="influenza" post="except when indicated for treatment of underlying medical conditions"/>
 <result pre="indicated for treatment of underlying medical conditions (e.g., COPD or" exact="asthma" post="exacerbation) or septic shock. Risk factors Influenza vaccination is"/>
 <result pre="Risk factors Influenza vaccination is the primary method for preventing" exact="influenza" post="and reducing the risk of severe outcomes. In the"/>
 <result pre="U.S., the Advisory Committee on Immunization Practices (ACIP) recommends annual" exact="influenza" post="vaccination for all persons aged 6 months and older and"/>
 <result pre="6 months and older and prioritizes those at higher risk for" exact="influenza" post="complications [10]. High-risk groups include adults aged &amp;gt; 65 years [11,"/>
 <result pre="who might be at risk for experiencing Reye syndrome with" exact="influenza" post="virus infection, and those who are extremely obese (BMI"/>
 <result pre="complications [10, 19–23]. Table 2 Groups at high risk for" exact="influenza" post="complications* Risk factors for severe influenza outcomes • Age"/>
 <result pre="at high risk for influenza complications* Risk factors for severe" exact="influenza" post="outcomes • Age &amp;lt; 5 years, especially those &amp;lt; 2 years • Age"/>
 <result pre="those &amp;lt; 2 years • Age &amp;gt; 65 years • Pregnant women • Extreme" exact="obesity" post="(BMI &amp;gt; 40 kg/m2) • Native Americans/Alaskan Natives (may also"/>
 <result pre="on Immunization Practices Many studies evaluated risk factors for severe" exact="influenza" post="during the 2009 H1N1 influenza pandemic. Adult ICU patients"/>
 <result pre="evaluated risk factors for severe influenza during the 2009 H1N1" exact="influenza" post="pandemic. Adult ICU patients with influenza A(H1N1)pdm09 virus infection"/>
 <result pre="during the 2009 H1N1 influenza pandemic. Adult ICU patients with" exact="influenza" post="A(H1N1)pdm09 virus infection were primarily non-elderly, were obese [24–28],"/>
 <result pre="[24–28], and had higher odds of death, invasive mechanical ventilation," exact="acute respiratory distress syndrome" post="(ARDS), septic shock, and multi-lobar pneumonia when compared with"/>
 <result pre="ventilation, acute respiratory distress syndrome (ARDS), septic shock, and multi-lobar" exact="pneumonia" post="when compared with seasonal influenza patients [24, 29]. In"/>
 <result pre="(ARDS), septic shock, and multi-lobar pneumonia when compared with seasonal" exact="influenza" post="patients [24, 29]. In children, independent risk factors for"/>
 <result pre="influenza patients [24, 29]. In children, independent risk factors for" exact="influenza" post="A(H1N1)pdm09-related mortality included chronic neurologic condition or immune compromise,"/>
 <result pre="influenza A(H1N1)pdm09-related mortality included chronic neurologic condition or immune compromise," exact="acute myocarditis" post="or encephalitis, and early presumed MRSA co-infection of the"/>
 <result pre="A(H1N1)pdm09-related mortality included chronic neurologic condition or immune compromise, acute" exact="myocarditis" post="or encephalitis, and early presumed MRSA co-infection of the"/>
 <result pre="Bacterial co-infection was identified in approximately one third of fatal" exact="influenza" post="A(H1N1)pdm09 cases in the largest autopsy case series [31]."/>
 <result pre="in the inter-pandemic period are also common in critically ill" exact="influenza" post="patients [32]. One study identified past or current tobacco"/>
 <result pre="study reported that mortality was higher in immunosuppressed patients with" exact="influenza" post="A(H1N1)pdm09 than in immunocompetent patients [34]. Severity of influenza"/>
 <result pre="with influenza A(H1N1)pdm09 than in immunocompetent patients [34]. Severity of" exact="influenza" post="seasons varies from year-to-year based on the predominant influenza"/>
 <result pre="of influenza seasons varies from year-to-year based on the predominant" exact="influenza" post="viruses, and between seasonal and pandemic influenza [35, 36]."/>
 <result pre="on the predominant influenza viruses, and between seasonal and pandemic" exact="influenza" post="[35, 36]. One study reported that patients with influenza"/>
 <result pre="pandemic influenza [35, 36]. One study reported that patients with" exact="influenza" post="A(H1N1)pdm09 had higher odds of severe disease than patients"/>
 <result pre="had higher odds of severe disease than patients with either" exact="influenza" post="A(H3N2) or influenza B virus infections [37]. However, influenza"/>
 <result pre="of severe disease than patients with either influenza A(H3N2) or" exact="influenza" post="B virus infections [37]. However, influenza B virus infection"/>
 <result pre="either influenza A(H3N2) or influenza B virus infections [37]. However," exact="influenza" post="B virus infection has been shown to increase the"/>
 <result pre="increase the odds of in-hospital mortality in children compared with" exact="influenza" post="A virus infection [38]. Prevention and vaccination Influenza vaccination"/>
 <result pre="&amp;gt; 6 months in the U.S. and should continue as long as" exact="influenza" post="viruses are circulating in the community. Previously unvaccinated children"/>
 <result pre="6 months through 8 years require two doses 1 month apart. Since" exact="influenza" post="vaccine effectiveness (VE) to prevent medically attended illness varies"/>
 <result pre="and immune function, some vaccinated individuals can become symptomatic with" exact="influenza" post="virus infection. However, several studies have reported influenza vaccine"/>
 <result pre="symptomatic with influenza virus infection. However, several studies have reported" exact="influenza" post="vaccine effectiveness in reducing illness severity, including reducing severe"/>
 <result pre="reduced a half-day in patients aged 50–64 years who had received" exact="influenza" post="vaccination compared with unvaccinated patients [41]. A study across"/>
 <result pre="[41]. A study across all age groups in Spain reported" exact="influenza" post="VE of 58% in reducing the risk of severe"/>
 <result pre="influenza VE of 58% in reducing the risk of severe" exact="influenza" post="requiring hospitalization [42]. A Southern Hemisphere study reported influenza"/>
 <result pre="severe influenza requiring hospitalization [42]. A Southern Hemisphere study reported" exact="influenza" post="VE of 82% in reducing influenza-associated ICU admissions among"/>
 <result pre="adults [43] while a study in Spain showed an adjusted" exact="influenza" post="VE of 23% in preventing ICU admission and death"/>
 <result pre="preventing ICU admission and death [44]. Despite the benefits of" exact="influenza" post="vaccination, there continues to be low vaccine coverage among"/>
 <result pre="high prevalence of high-risk comorbidities [45, 46]. In children, low" exact="influenza" post="vaccination coverage has also been reported among those admitted"/>
 <result pre="ICUs, even among those with underlying high-risk conditions [47]. Full" exact="influenza" post="vaccination was shown to result in a 74% reduction"/>
 <result pre="in pediatric ICU admissions compared to unvaccinated or partially vaccinated" exact="influenza" post="patients [47]. Furthermore, one study showed that influenza VE"/>
 <result pre="partially vaccinated influenza patients [47]. Furthermore, one study showed that" exact="influenza" post="VE was 65% in reducing the risk of mortality"/>
 <result pre="the U.S. [48]. These data further emphasize the benefits of" exact="influenza" post="vaccination in reducing severe influenza complications, especially in high-risk"/>
 <result pre="further emphasize the benefits of influenza vaccination in reducing severe" exact="influenza" post="complications, especially in high-risk persons. Diagnosis Persons with uncomplicated"/>
 <result pre="influenza complications, especially in high-risk persons. Diagnosis Persons with uncomplicated" exact="influenza" post="typically experience acute onset of respiratory symptoms (cough, rhinorrhea,"/>
 <result pre="rhinorrhea, congestion), myalgias, and headache with or without fever. During" exact="influenza" post="season, clinicians should also consider influenza when there is"/>
 <result pre="or without fever. During influenza season, clinicians should also consider" exact="influenza" post="when there is only fever present or in patients"/>
 <result pre="who are afebrile and have respiratory symptoms [49]. Complications of" exact="influenza" post="vary by age, underlying comorbidities or high-risk conditions such"/>
 <result pre="multi-organ failure, exacerbation of an underlying condition such as chronic" exact="lung disease" post="[50, 51], heart failure [52], or other extrapulmonary complications"/>
 <result pre="failure [52], or other extrapulmonary complications including stroke, encephalopathy, or" exact="encephalitis" post="[30, 49, 53]. Influenza testing is recommended for all"/>
 <result pre="with suspected influenza, including those admitted to the ICU during" exact="influenza" post="season with acute respiratory illness and community-acquired pneumonia, without"/>
 <result pre="alternative diagnosis. Furthermore, all individuals requiring critical care outside of" exact="influenza" post="season should be tested for influenza if there is"/>
 <result pre="critical care outside of influenza season should be tested for" exact="influenza" post="if there is a possible epidemiological link to an"/>
 <result pre="individual with recent influenza, such as travel to areas with" exact="influenza" post="activity or exposure to an institutional influenza outbreak. Special"/>
 <result pre="to areas with influenza activity or exposure to an institutional" exact="influenza" post="outbreak. Special consideration should be given to elderly and"/>
 <result pre="consideration should be given to elderly and immunocompromised patients, as" exact="influenza" post="virus infection may not present with typical acute respiratory"/>
 <result pre="of America (IDSA) 2018 Influenza Clinical Practice Guidelines also recommend" exact="influenza" post="testing for patients at high risk of complications such"/>
 <result pre="such as exacerbation of chronic cardiopulmonary disease [49]. Diagnosis of" exact="influenza" post="should be made as soon as possible in critically"/>
 <result pre="have reported an increase in mortality of ICU patients with" exact="influenza" post="A(H1N1)pdm09 virus infection when diagnosis was delayed [54], and"/>
 <result pre="was initiated within 6 h of admission [55]. Several kinds of" exact="influenza" post="diagnostic tests are available in clinical settings with variable"/>
 <result pre="the clinician to properly interpret their results. Most studies of" exact="influenza" post="diagnostic accuracy have been conducted on specimens from patients"/>
 <result pre="with uncomplicated influenza, and few have assessed the performance of" exact="influenza" post="tests in critically ill patients. The IDSA guidelines recommend"/>
 <result pre="tests in critically ill patients. The IDSA guidelines recommend molecular" exact="influenza" post="assays for testing respiratory specimens from all hospitalized patients"/>
 <result pre="for testing respiratory specimens from all hospitalized patients with suspected" exact="influenza" post="because of their high sensitivity, specificity, and time to"/>
 <result pre="results (15 min to several hours) [49]. The use of rapid" exact="influenza" post="molecular diagnostic testing can result in better outcomes for"/>
 <result pre="or throat NP or BAL/mini BAL Nasal or endotracheal Rapid" exact="influenza" post="diagnostic Test (RIDT) Antigen detection 10–15 min Low to moderate"/>
 <result pre="Some molecular assays also detect other respiratory pathogens #Patients with" exact="respiratory failure" post="and suspected influenza should have lower respiratory tract specimens"/>
 <result pre="detect other respiratory pathogens #Patients with respiratory failure and suspected" exact="influenza" post="should have lower respiratory tract specimens collected and tested,"/>
 <result pre="tested, including if upper respiratory tract specimens are negative for" exact="influenza" post="because a patient may have cleared influenza virus from"/>
 <result pre="are negative for influenza because a patient may have cleared" exact="influenza" post="virus from the upper respiratory tract and continue to"/>
 <result pre="virus from the upper respiratory tract and continue to have" exact="influenza" post="viral replication in the lower respiratory tract NP nasopharyngeal,"/>
 <result pre="recommended for diagnosis or clinical management of patients with suspected" exact="influenza" post="A recent meta-analysis reported that influenza antigen detection tests"/>
 <result pre="of patients with suspected influenza A recent meta-analysis reported that" exact="influenza" post="antigen detection tests that produce rapid results had very"/>
 <result pre="but sensitivities were highly variable compared with RT-PCR [58]. Rapid" exact="influenza" post="diagnostic tests (RIDTs) without an analyzer device had only"/>
 <result pre="device (digital immunoassays) had moderately high sensitivity (77–80%), and rapid" exact="influenza" post="molecular assays (nucleic acid detection) had high sensitivity (92–95%)"/>
 <result pre="high sensitivity (92–95%) [58]. Low sensitivity of RIDTs for detecting" exact="influenza" post="virus in ICU patients has been reported [59]. Recently,"/>
 <result pre="has been reported [59]. Recently, a systematic analysis of rapid" exact="influenza" post="molecular tests from 29 studies reported pooled sensitivity and"/>
 <result pre="97.4%, respectively [60]. Therefore, antigen detection assays, such as rapid" exact="influenza" post="diagnostic tests and immunofluorescence assays, are not recommended for"/>
 <result pre="immunofluorescence assays, are not recommended for hospitalized patients with suspected" exact="influenza" post="because of their lower sensitivities, unless molecular assays are"/>
 <result pre="unless molecular assays are not available [49]. Negative results for" exact="influenza" post="based on tests with low sensitivity (e.g., RIDTs, immunofluorescence"/>
 <result pre="up with reverse transcription polymerase chain reaction (RT-PCR) or other" exact="influenza" post="molecular assays to confirm results, and antiviral treatment should"/>
 <result pre="should continue until results are available. Preferred respiratory specimens for" exact="influenza" post="testing in hospitalized patients without lower respiratory tract disease"/>
 <result pre="tract specimens should be considered in hospitalized patients with suspected" exact="influenza" post="if upper respiratory tract specimens are negative and a"/>
 <result pre="31]. In hospitalized patients receiving invasive mechanical ventilation in whom" exact="influenza" post="is suspected, but not yet diagnosed, influenza testing should"/>
 <result pre="ventilation in whom influenza is suspected, but not yet diagnosed," exact="influenza" post="testing should be performed on endotracheal aspirate specimens instead"/>
 <result pre="the upper respiratory tract [61]. Molecular testing, including RT-PCR for" exact="influenza" post="viruses can also be performed on bronchoalveolar lavage (BAL)"/>
 <result pre="have very low diagnostic yield and are not recommended for" exact="influenza" post="testing [49]. Diagnostic test results on specimens collected from"/>
 <result pre="making even for patients with extra-pulmonary complications of influenza. Novel" exact="influenza" post="A viruses are typically of animal origin, differ antigenically"/>
 <result pre="animal origin, differ antigenically and genetically from currently circulating seasonal" exact="influenza" post="A viruses (including H1N1pdm09 and H3N2 subtypes) and have"/>
 <result pre="H3N2 subtypes) and have infected at least one person. Novel" exact="influenza" post="A viruses can cause a wide clinical spectrum of"/>
 <result pre="and multi-organ failure [62] and human infection with a novel" exact="influenza" post="A virus is of public health concern. In the"/>
 <result pre="health concern. In the U.S., human infection with a novel" exact="influenza" post="A virus is nationally reportable to the Centers for"/>
 <result pre="Health Organization. A major concern is the risk of novel" exact="influenza" post="A virus transmission among humans; depending upon the prevalence"/>
 <result pre="upon the prevalence of pre-existing immunity in the population, novel" exact="influenza" post="A viruses may have pandemic potential. Patients suspected with"/>
 <result pre="A viruses may have pandemic potential. Patients suspected with novel" exact="influenza" post="A virus infection should be investigated for a possible"/>
 <result pre="close contact to an individual with suspected or confirmed novel" exact="influenza" post="A virus infection. Novel influenza A virus infection cannot"/>
 <result pre="with suspected or confirmed novel influenza A virus infection. Novel" exact="influenza" post="A virus infection cannot be distinguished from seasonal influenza"/>
 <result pre="Novel influenza A virus infection cannot be distinguished from seasonal" exact="influenza" post="A virus infection by clinical findings or testing at"/>
 <result pre="RT-PCR at public health laboratories [63]. Cases of suspected novel" exact="influenza" post="A virus infections should be discussed with appropriate local"/>
 <result pre="to coordinate the testing of appropriate respiratory specimens. Treatment of" exact="influenza" post="Treatment of severe influenza presents multiple challenges. The mainstay"/>
 <result pre="of appropriate respiratory specimens. Treatment of influenza Treatment of severe" exact="influenza" post="presents multiple challenges. The mainstay of therapy for patients"/>
 <result pre="presents multiple challenges. The mainstay of therapy for patients with" exact="influenza" post="is initiation of antiviral medication as soon as possible"/>
 <result pre="rimantadine) (Table 4). NAIs and baloxavir have activity against both" exact="influenza" post="A and B viruses. Adamantanes only have activity against"/>
 <result pre="influenza A and B viruses. Adamantanes only have activity against" exact="influenza" post="A viruses and are not recommended for treatment of"/>
 <result pre="influenza A viruses and are not recommended for treatment of" exact="influenza" post="due to widespread resistance among currently circulating strains of"/>
 <result pre="due to widespread resistance among currently circulating strains of seasonal" exact="influenza" post="A viruses. Notably, FDA-approved antiviral medications for treatment of"/>
 <result pre="influenza A viruses. Notably, FDA-approved antiviral medications for treatment of" exact="influenza" post="are approved for early treatment of uncomplicated influenza in"/>
 <result pre="treatment of influenza are approved for early treatment of uncomplicated" exact="influenza" post="in outpatients based upon randomized placebo-controlled clinical trials conducted"/>
 <result pre="of randomized placebo-controlled clinical trials of early oseltamivir treatment of" exact="influenza" post="in pediatric and adult outpatients have reported clinical benefit"/>
 <result pre="duration of illness and risk for some complications associated with" exact="influenza" post="[65, 66]. Table 4 Antiviral treatment Antiviral agents and"/>
 <result pre="A phase III clinical trial of baloxavir treatment of hospitalized" exact="influenza" post="patients is ongoing: https://clinicaltrials.gov/ct2/show/NCT03684044 No completed randomized, placebo-controlled trials"/>
 <result pre="placebo-controlled trials of antiviral treatment have been conducted in hospitalized" exact="influenza" post="patients to establish the efficacy of oseltamivir or other"/>
 <result pre="treatment (&amp;gt; 48 h), and a 69% reduction in mortality risk between" exact="influenza" post="patients receiving early NAI treatment and those who did"/>
 <result pre="underpowered because death is less common in hospitalized children with" exact="influenza" post="than in adults. Although studies have shown the greatest"/>
 <result pre="median duration of ICU hospitalization in severely ill patients with" exact="influenza" post="A(H3N2), but not A(H1N1pdm09) or B virus infection in"/>
 <result pre="reported delays in initiation of oseltamivir treatment prescribed to hospitalized" exact="influenza" post="patients and suggested empiric administration of oseltamivir treatment in"/>
 <result pre="for patients being admitted with lower respiratory tract disease during" exact="influenza" post="season [79]. Overall, based upon available observational data to"/>
 <result pre="of therapy with neuraminidase inhibitors are limited in critically ill" exact="influenza" post="patients. Enterically administered oseltamivir is the preferred treatment for"/>
 <result pre="patients and the risk of bronchospasm in patients with underlying" exact="lung disease." post="Studies indicate that oseltamivir administered orally or via oro/naso-gastric"/>
 <result pre="not provide additional clinical benefit in obese adults, including extreme" exact="obesity" post="(BMI &amp;gt; 40) [93, 94]. Duration of therapy can be"/>
 <result pre="Duration of therapy can be difficult to define, as prolonged" exact="influenza" post="viral replication and shedding from the both upper and"/>
 <result pre="also help reduce the pro-inflammatory dysregulated cytokine response triggered by" exact="influenza" post="virus infection and reduce nosocomial influenza virus transmission to"/>
 <result pre="cytokine response triggered by influenza virus infection and reduce nosocomial" exact="influenza" post="virus transmission to healthcare personnel in the ICU. Consultation"/>
 <result pre="should be considered for ICU patients with evidence of persistent" exact="influenza" post="viral replication after NAI treatment, particularly in severely immunocompromised"/>
 <result pre="enteric oseltamivir [101]. Notably, a randomized trial conducted in three" exact="influenza" post="seasons found similar clinical outcomes between IV peramivir and"/>
 <result pre="outcomes between IV peramivir and enteric oseltamivir in hospitalized adult" exact="influenza" post="patients [102]; a separate trial did not identify significant"/>
 <result pre="clinical benefit between enteric oseltamivir and intravenous peramivir in hospitalized" exact="influenza" post="patients [104]. In 2018, a novel antiviral agent, baloxavir"/>
 <result pre="agent, baloxavir marboxil, was FDA-approved for early treatment of uncomplicated" exact="influenza" post="in outpatients aged ≥ 12 years old. Baloxavir acts via inhibition"/>
 <result pre="outpatients aged ≥ 12 years old. Baloxavir acts via inhibition of the" exact="influenza" post="virus cap-dependent endonuclease, a different mechanism than the neuraminidase"/>
 <result pre="different mechanism than the neuraminidase inhibitors, and can treat NAI-resistant" exact="influenza" post="virus infections. Randomized controlled trials of single-dose oral baloxavir"/>
 <result pre="or in combination with an NAI for treatment of hospitalized" exact="influenza" post="patients is unclear. Specifically, optimal dosing, duration of therapy,"/>
 <result pre="have yet to be determined for baloxavir treatment of hospitalized" exact="influenza" post="patients. In the outpatient RCT, patients treated with single-dose"/>
 <result pre="RCT, patients treated with single-dose baloxavir showed significant reduction in" exact="influenza" post="viral levels in the upper respiratory tract at 24 h"/>
 <result pre="oseltamivir [105]. However, it is unknown whether this reduction in" exact="influenza" post="viral shedding correlates with reduced transmissibility. A potential concern"/>
 <result pre="baloxavir in combination with oseltamivir versus oseltamivir monotherapy in hospitalized" exact="influenza" post="patients is currently enrolling participants [107]. There are no"/>
 <result pre="no completed randomized clinical trials of adjunctive corticosteroid treatment in" exact="influenza" post="patients. A trial of corticosteroid therapy was planned during"/>
 <result pre="tripled the risk of developing critical illness or death from" exact="influenza" post="A(H1N1)pdm09 virus infection [109]. A re-analysis of prospectively collected"/>
 <result pre="infection [109]. A re-analysis of prospectively collected data on 1846" exact="influenza" post="patients admitted with primary influenza pneumonia to 148 ICUs"/>
 <result pre="prospectively collected data on 1846 influenza patients admitted with primary" exact="influenza" post="pneumonia to 148 ICUs in Spain during 2009–2014 using"/>
 <result pre="collected data on 1846 influenza patients admitted with primary influenza" exact="pneumonia" post="to 148 ICUs in Spain during 2009–2014 using propensity"/>
 <result pre="observational studies have concluded that that corticosteroid treatment of hospitalized" exact="influenza" post="patients does not result in better outcomes and may"/>
 <result pre="have also reported potential association between corticosteroid treatment and adverse" exact="influenza" post="outcomes [30, 114, 115]. A recent Cochrane review of"/>
 <result pre="suggested increased mortality when adjunctive corticosteroid therapy is used for" exact="influenza" post="patients; however, the available evidence was of low quality"/>
 <result pre="studies have reported that corticosteroid treatment is associated with prolonged" exact="influenza" post="viral shedding in hospitalized patients [117–119], including in sporadic"/>
 <result pre="in hospitalized patients [117–119], including in sporadic human infections with" exact="avian influenza" post="A(H7N9) virus in China [120], and increased rates of"/>
 <result pre="hospitalized patients [117–119], including in sporadic human infections with avian" exact="influenza" post="A(H7N9) virus in China [120], and increased rates of"/>
 <result pre="not well understood. One observational study of hospitalized patients with" exact="viral pneumonia" post="due to avian influenza A(H7N9) virus infection in China"/>
 <result pre="well understood. One observational study of hospitalized patients with viral" exact="pneumonia" post="due to avian influenza A(H7N9) virus infection in China"/>
 <result pre="observational study of hospitalized patients with viral pneumonia due to" exact="avian influenza" post="A(H7N9) virus infection in China reported that high-dose, but"/>
 <result pre="study of hospitalized patients with viral pneumonia due to avian" exact="influenza" post="A(H7N9) virus infection in China reported that high-dose, but"/>
 <result pre="unless clinically indicated for another reason, such as treatment of" exact="asthma" post="or COPD exacerbation or septic shock [49]. Further studies"/>
 <result pre="benefit or harms associated with corticosteroid treatment of critically ill" exact="influenza" post="patients. Although neuraminidase inhibitors (oseltamivir) are currently recommended for"/>
 <result pre="neuraminidase inhibitors (oseltamivir) are currently recommended for antiviral treatment of" exact="influenza" post="in hospitalized patients based on observational studies, including in"/>
 <result pre="are a number of novel strategies and products for treating" exact="influenza" post="in various stages of development. One approach under investigation"/>
 <result pre="therapy, which combines amantadine, ribavirin, and oseltamivir for treatment of" exact="influenza" post="in critically ill and high-risk patients. Unfortunately, studies to"/>
 <result pre="of monoclonal and polyclonal antibodies, targeted against a variety of" exact="influenza" post="viral proteins, are also in development [130–133]. Similarly, convalescent"/>
 <result pre="interest is the modification of the host antiviral response to" exact="influenza" post="virus infection. There are ongoing preclinical and clinical studies"/>
 <result pre="at risk for severe complications of influenza. A diagnosis of" exact="influenza" post="should be considered in critically ill patients admitted with"/>
 <result pre="such as exacerbation of underlying chronic comorbidities, community-acquired pneumonia, and" exact="respiratory failure" post="during influenza season. Influenza molecular assays are recommended for"/>
 <result pre="of underlying chronic comorbidities, community-acquired pneumonia, and respiratory failure during" exact="influenza" post="season. Influenza molecular assays are recommended for testing upper"/>
 <result pre="ill patients with lower respiratory tract disease may have cleared" exact="influenza" post="virus in the upper respiratory tract, but have prolonged"/>
 <result pre="influenza virus in the upper respiratory tract, but have prolonged" exact="influenza" post="viral replication in the lower respiratory tract, an endotracheal"/>
 <result pre="is recommended as soon as possible for patients with suspected" exact="influenza" post="without waiting for testing results. Corticosteroids should not be"/>
 <result pre="results. Corticosteroids should not be routinely administered for treatment of" exact="influenza" post="and should only be given for other indications (e.g.,"/>
 <result pre="should only be given for other indications (e.g., exacerbation of" exact="asthma" post="or chronic obstructive pulmonary disease, or septic shock), because"/>
 <result pre="be given for other indications (e.g., exacerbation of asthma or" exact="chronic obstructive pulmonary disease," post="or septic shock), because of the risk for prolongation"/>
 <result pre="or septic shock), because of the risk for prolongation of" exact="influenza" post="viral shedding and ventilator-associated pneumonia in critically ill influenza"/>
 <result pre="the risk for prolongation of influenza viral shedding and ventilator-associated" exact="pneumonia" post="in critically ill influenza patients with respiratory failure. Future"/>
 <result pre="of influenza viral shedding and ventilator-associated pneumonia in critically ill" exact="influenza" post="patients with respiratory failure. Future directions for treatment of"/>
 <result pre="shedding and ventilator-associated pneumonia in critically ill influenza patients with" exact="respiratory failure." post="Future directions for treatment of influenza in critically ill"/>
 <result pre="influenza patients with respiratory failure. Future directions for treatment of" exact="influenza" post="in critically ill patients include novel antiviral compounds, combination"/>
 <result pre="the U.S. CDC’s Advisory Committee on Immunization Practices recommendations for" exact="influenza" post="vaccination. This may also apply to indigenous people from"/>
 <result pre="and institutional affiliations. References References 1.JacksonMLPhillipsCHBenoitJet al.Burden of medically attended" exact="influenza" post="infection and cases averted by vaccination - United States,"/>
 <result pre="cases averted by vaccination - United States, 2013/14 through 2015/16" exact="influenza" post="seasonsVaccine201836446747210.1016/j.vaccine.2017.12.01429249545 2.IulianoADRoguskiKMChangHHet al.Estimates of global seasonal influenza-associated respiratory mortality:"/>
 <result pre="and subtropics - when to vaccinate?PLoS One2016114e015300310.1371/journal.pone.015300327119988 5.TinocoYOAzziz-BaumgartnerEUyekiTMet al.Burden of" exact="influenza" post="in 4 ecologically distinct regions of Peru: household active"/>
 <result pre="of a community cohort, 2009-2015Clin Infect Dis20176591532154110.1093/cid/cix56529020267 6.YangWCummingsMJBakamutumahoBet al.Dynamics of" exact="influenza" post="in tropical Africa: temperature, humidity, and co-circulating (sub)typesInfluenza Other"/>
 <result pre="and co-circulating (sub)typesInfluenza Other Respir Viruses201812444645610.1111/irv.1255629573157 7.TokarsJIOlsenSJReedCSeasonal incidence of symptomatic" exact="influenza" post="in the United StatesClin Infect Dis201866101511151810.1093/cid/cix106029206909 8.Centers for Disease"/>
 <result pre="Available at: https://www.cdc.gov/flu/about/burden/index.html. Accessed 24 Apr 2019. 9.ReedCChavesSSDaily KirleyPet al.Estimating" exact="influenza" post="disease burden from population-based surveillance data in the United"/>
 <result pre="in the United StatesPLoS One2015103e011836910.1371/journal.pone.011836925738736 10.GrohskopfLASokolowLZBroderKRWalterEBFryAMJerniganDBPrevention and control of seasonal" exact="influenza" post="with vaccines: recommendations of the advisory committee on immunization"/>
 <result pre="recommendations of the advisory committee on immunization practices-United States, 2018-19" exact="influenza" post="seasonMMWR Recomm Rep201867312010.15585/mmwr.rr6703a130141464 11.BarkerWHExcess pneumonia and influenza associated hospitalization"/>
 <result pre="on immunization practices-United States, 2018-19 influenza seasonMMWR Recomm Rep201867312010.15585/mmwr.rr6703a130141464 11.BarkerWHExcess" exact="pneumonia" post="and influenza associated hospitalization during influenza epidemics in the"/>
 <result pre="practices-United States, 2018-19 influenza seasonMMWR Recomm Rep201867312010.15585/mmwr.rr6703a130141464 11.BarkerWHExcess pneumonia and" exact="influenza" post="associated hospitalization during influenza epidemics in the United States,"/>
 <result pre="seasonMMWR Recomm Rep201867312010.15585/mmwr.rr6703a130141464 11.BarkerWHExcess pneumonia and influenza associated hospitalization during" exact="influenza" post="epidemics in the United States, 1970-78Am J Public Health198676776176510.2105/AJPH.76.7.7613717461"/>
 <result pre="States, 1970-78Am J Public Health198676776176510.2105/AJPH.76.7.7613717461 12.BarkerWHMulloolyJPImpact of epidemic type A" exact="influenza" post="in a defined adult populationAm J Epidemiol1980112679881110.1093/oxfordjournals.aje.a1130527457471 13.PoehlingKAEdwardsKMGriffinMRet al.The"/>
 <result pre="a defined adult populationAm J Epidemiol1980112679881110.1093/oxfordjournals.aje.a1130527457471 13.PoehlingKAEdwardsKMGriffinMRet al.The burden of" exact="influenza" post="in young children, 2004-2009Pediatrics2013131220721610.1542/peds.2012-125523296444 14.PoehlingKAEdwardsKMWeinbergGAet al.The underrecognized burden of"/>
 <result pre="influenza in young children, 2004-2009Pediatrics2013131220721610.1542/peds.2012-125523296444 14.PoehlingKAEdwardsKMWeinbergGAet al.The underrecognized burden of" exact="influenza" post="in young childrenN Engl J Med20063551314010.1056/NEJMoa05486916822994 15.SistonAMRasmussenSAHoneinMAet al.Pandemic 2009"/>
 <result pre="influenza in young childrenN Engl J Med20063551314010.1056/NEJMoa05486916822994 15.SistonAMRasmussenSAHoneinMAet al.Pandemic 2009" exact="influenza" post="A(H1N1) virus illness among pregnant women in the United"/>
 <result pre="StatesJAMA2010303151517152510.1001/jama.2010.47920407061 16.MertzDGeraciJWinkupJGessnerBDOrtizJRLoebMPregnancy as a risk factor for severe outcomes from" exact="influenza" post="virus infection: a systematic review and meta-analysis of observational"/>
 <result pre="and meta-analysis of observational studiesVaccine201735452152810.1016/j.vaccine.2016.12.01228024955 17.LouieJKAcostaMJamiesonDJHoneinMAcollab: Group CPHNWSevere 2009 H1N1" exact="influenza" post="in pregnant and postpartum women in CaliforniaN Engl J"/>
 <result pre="and postpartum women in CaliforniaN Engl J Med20103621273510.1056/NEJMoa091044420032319 18.LouieJKJamiesonDJRasmussenSA2009 Pandemic" exact="influenza" post="a (H1N1) virus infection in postpartum women in CaliforniaAm"/>
 <result pre="among adultsVaccine200725584685510.1016/j.vaccine.2006.09.04117074423 22.MertzDKimTHJohnstoneJet al.Populations at risk for severe or complicated" exact="influenza" post="illness: systematic review and meta-analysisBMJ2013347f506110.1136/bmj.f506123974637 23.Van KerkhoveMDVandemaeleKAShindeVet al.Risk factors"/>
 <result pre="meta-analysisBMJ2013347f506110.1136/bmj.f506123974637 23.Van KerkhoveMDVandemaeleKAShindeVet al.Risk factors for severe outcomes following 2009" exact="influenza" post="A (H1N1) infection: a global pooled analysisPLoS Med201187e100105310.1371/journal.pmed.100105321750667 24.RelloJRodriguezAIbanezPet"/>
 <result pre="pooled analysisPLoS Med201187e100105310.1371/journal.pmed.100105321750667 24.RelloJRodriguezAIbanezPet al.Intensive care adult patients with severe" exact="respiratory failure" post="caused by influenza A (H1N1)v in SpainCrit Care2009135R14810.1186/cc804419747383 25.RiceTWRubinsonLUyekiTMet"/>
 <result pre="al.Intensive care adult patients with severe respiratory failure caused by" exact="influenza" post="A (H1N1)v in SpainCrit Care2009135R14810.1186/cc804419747383 25.RiceTWRubinsonLUyekiTMet al.Critical illness from"/>
 <result pre="(H1N1)v in SpainCrit Care2009135R14810.1186/cc804419747383 25.RiceTWRubinsonLUyekiTMet al.Critical illness from 2009 pandemic" exact="influenza" post="A virus and bacterial coinfection in the United StatesCrit"/>
 <result pre="StatesCrit Care Med20124051487149810.1097/CCM.0b013e3182416f2322511131 26.WebbSAPettiläVSeppeltIet al.Critical care services and 2009 H1N1" exact="influenza" post="in Australia and New ZealandN Engl J Med2009361201925193410.1056/NEJMoa090848119815860 27.Domínguez-CheritGLapinskySEMaciasAEet"/>
 <result pre="ZealandN Engl J Med2009361201925193410.1056/NEJMoa090848119815860 27.Domínguez-CheritGLapinskySEMaciasAEet al.Critically ill patients with 2009" exact="influenza" post="A(H1N1) in MexicoJAMA2009302171880188710.1001/jama.2009.153619822626 28.KumarAZarychanskiRPintoRet al.Critically ill patients with 2009"/>
 <result pre="influenza A(H1N1) in MexicoJAMA2009302171880188710.1001/jama.2009.153619822626 28.KumarAZarychanskiRPintoRet al.Critically ill patients with 2009" exact="influenza" post="A(H1N1) infection in CanadaJAMA2009302171872187910.1001/jama.2009.149619822627 29.MincholeEFigueredoALOmeñacaMet al.Seasonal influenza a H1N1pdm09"/>
 <result pre="patients with 2009 influenza A(H1N1) infection in CanadaJAMA2009302171872187910.1001/jama.2009.149619822627 29.MincholeEFigueredoALOmeñacaMet al.Seasonal" exact="influenza" post="a H1N1pdm09 virus and severe outcomes: a reason for"/>
 <result pre="People PLoS One20161111e016571110.1371/journal.pone.016571127832114 30.RandolphAGVaughnFSullivanRet al.Critically ill children during the 2009-2010" exact="influenza" post="pandemic in the United StatesPediatrics20111286e1450e145810.1542/peds.2011-077422065262 31.ShiehWJBlauDMDenisonAMet al.2009 pandemic influenza"/>
 <result pre="2009-2010 influenza pandemic in the United StatesPediatrics20111286e1450e145810.1542/peds.2011-077422065262 31.ShiehWJBlauDMDenisonAMet al.2009 pandemic" exact="influenza" post="A (H1N1): pathology and pathogenesis of 100 fatal cases"/>
 <result pre="and treatment-related risk factors for mortality among immunosuppressed patients with" exact="influenza" post="A (H1N1) virus admitted to the intensive care unitJ"/>
 <result pre="al.Complications among adults hospitalized with influenza: a comparison of seasonal" exact="influenza" post="and the 2009 H1N1 pandemicClin Infect Dis201459216617410.1093/cid/ciu28524785230 36.AyscuePMurrayEUyekiTet al.Influenza-associated"/>
 <result pre="2014MMWR Morb Mortal Wkly Rep201463714314724553197 37.ChavesSSAragonDBennettNet al.Patients hospitalized with laboratory-confirmed" exact="influenza" post="during the 2010-2011 influenza season: exploring disease severity by"/>
 <result pre="Rep201463714314724553197 37.ChavesSSAragonDBennettNet al.Patients hospitalized with laboratory-confirmed influenza during the 2010-2011" exact="influenza" post="season: exploring disease severity by virus type and subtypeJ"/>
 <result pre="in children, FluSurv-NET, 2011–2017Open Forum Infectious Dis20185suppl_1S748S7S910.1093/ofid/ofy210.2146 39.CasadoIDomínguezAToledoDet al.Effect of" exact="influenza" post="vaccination on the prognosis of hospitalized influenza patientsExpert Rev"/>
 <result pre="39.CasadoIDomínguezAToledoDet al.Effect of influenza vaccination on the prognosis of hospitalized" exact="influenza" post="patientsExpert Rev Vaccines201615342543210.1586/14760584.2016.113432826690376 40.ArriolaCGargSAndersonEJet al.Influenza vaccination modifies disease severity"/>
 <result pre="among community-dwelling adults hospitalized with influenzaClin Infect Dis20176581289129710.1093/cid/cix46828525597 41.ArriolaCSAndersonEJBaumbachJet al.Does" exact="influenza" post="vaccination modify influenza severity? Data on older adults hospitalized"/>
 <result pre="hospitalized with influenzaClin Infect Dis20176581289129710.1093/cid/cix46828525597 41.ArriolaCSAndersonEJBaumbachJet al.Does influenza vaccination modify" exact="influenza" post="severity? Data on older adults hospitalized with influenza during"/>
 <result pre="vaccination modify influenza severity? Data on older adults hospitalized with" exact="influenza" post="during the 2012-2013 season in the United StatesJ Infect"/>
 <result pre="Catalonia. Influenza vaccine effectiveness in reducing severe outcomes over six" exact="influenza" post="seasons, a case-case analysis, Spain, 2010/11 to 2015/16. Euro"/>
 <result pre="2018;23(43). 10.2807/1560-7917.ES.2018.23.43.1700732. 45.CataniaJQueLGGovertJAHollingsworthJWWolfeCRHigh intensive care unit admission rate for 2013-2014" exact="influenza" post="is associated with a low rate of vaccinationAm J"/>
 <result pre="vaccinationAm J Respir Crit Care Med2014189448548710.1164/rccm.201401-0066LE24512430 46.TaylorGAbdesselamKPeludeLet al.Epidemiological features of" exact="influenza" post="in Canadian adult intensive care unit patientsEpidemiol Infect2016144474175010.1017/S095026881500211326384310 47.FerdinandsJMOlshoLEAganAAet"/>
 <result pre="Canadian adult intensive care unit patientsEpidemiol Infect2016144474175010.1017/S095026881500211326384310 47.FerdinandsJMOlshoLEAganAAet al.Effectiveness of" exact="influenza" post="vaccine against life-threatening RT-PCR-confirmed influenza illness in US children,"/>
 <result pre="patientsEpidemiol Infect2016144474175010.1017/S095026881500211326384310 47.FerdinandsJMOlshoLEAganAAet al.Effectiveness of influenza vaccine against life-threatening RT-PCR-confirmed" exact="influenza" post="illness in US children, 2010-2012J Infect Dis2014210567468310.1093/infdis/jiu18524676207 48.FlanneryBrendanReynoldsSue B.BlantonLeneeSantibanezTammy"/>
 <result pre="frequently present as the infecting agent in acute exacerbations of" exact="chronic obstructive pulmonary disease" post="in patients presenting to hospitalIntern Med J201646101160116510.1111/imj.1321327515577 51.SandrockCENorrisAInfection in"/>
 <result pre="in patients presenting to hospitalIntern Med J201646101160116510.1111/imj.1321327515577 51.SandrockCENorrisAInfection in severe" exact="asthma" post="exacerbations and critical asthma syndromeClin Rev Allergy Immunol201548110411310.1007/s12016-014-8435-x24984968 52.PanhwarMuhammad"/>
 <result pre="hospitalIntern Med J201646101160116510.1111/imj.1321327515577 51.SandrockCENorrisAInfection in severe asthma exacerbations and critical" exact="asthma" post="syndromeClin Rev Allergy Immunol201548110411310.1007/s12016-014-8435-x24984968 52.PanhwarMuhammad S.KalraAnkurGuptaTanushKolteDhavalKheraSahilBhattDeepak L.GinwallaMahazarinEffect of Influenza"/>
 <result pre="burden of influenza: a review of the extra-pulmonary complications of" exact="influenza" post="infectionInfluenza Other Respir Viruses201711537239310.1111/irv.1247028745014 54.Alvarez-LermaFMarin-CorralJVilaCet al.Delay in diagnosis of"/>
 <result pre="influenza infectionInfluenza Other Respir Viruses201711537239310.1111/irv.1247028745014 54.Alvarez-LermaFMarin-CorralJVilaCet al.Delay in diagnosis of" exact="influenza" post="A (H1N1)pdm09 virus infection in critically ill patients and"/>
 <result pre="58.MerckxJWaliRSchillerIet al.Diagnostic accuracy of novel and traditional rapid tests for" exact="influenza" post="infection compared with reverse transcriptase polymerase chain reaction: a"/>
 <result pre="review and meta-analysisAnn Intern Med2017167639440910.7326/M17-084828869986 59.BlythCCIredellJRDwyerDERapid-test sensitivity for novel swine-origin" exact="influenza" post="A (H1N1) virus in humansN Engl J Med200936125249310.1056/NEJMc090904919923563 60.Vos"/>
 <result pre="molecular assays, RT-PCR, and other molecular assays for diagnosis of" exact="influenza" post="virus infection. Available at: https://www.cdc.gov/flu/professionals/diagnosis/molecular-assays.htm. Accessed 24 Apr 2019."/>
 <result pre="virus infection. Available at: https://www.cdc.gov/flu/professionals/diagnosis/molecular-assays.htm. Accessed 24 Apr 2019. 62.UyekiTMKatzJMJerniganDBNovel" exact="influenza" post="A viruses and pandemic threatsLancet2017389100852172217410.1016/S0140-6736(17)31274-628589883 63.UyekiTMInfluenzaAnn Intern Med20171675ITC33ITC4810.7326/AITC20170905028869984 64.Centers"/>
 <result pre="Available at: https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm. Accessed 24 Apr 2019. 65.DobsonJWhitleyRJPocockSMontoASOseltamivir treatment for" exact="influenza" post="in adults: a meta-analysis of randomised controlled trialsLancet201538599791729173710.1016/S0140-6736(14)62449-125640810 66.MaloshREMartinETHeikkinenTBrooksWAWhitleyRJMontoASEfficacy"/>
 <result pre="early treatment with oseltamivir in hospitalized patients with documented 2009" exact="influenza" post="A (H1N1): retrospective cohort studyJ Antimicrob Chemother20116651150510.1093/jac/dkr08921393197 68.CoffinSELeckermanKKerenRHallMLocalioRZaoutisTEOseltamivir shortens"/>
 <result pre="treatment on outcomes of public health importance during the 2009-2010" exact="influenza" post="a(H1N1) pandemic: a systematic review and meta-analysis in hospitalized"/>
 <result pre="inhibitors in reducing mortality in patients admitted to hospital with" exact="influenza" post="A H1N1pdm09 virus infection: a meta-analysis of individual participant"/>
 <result pre="al.Effectiveness of antiviral treatment in preventing death in severe hospitalised" exact="influenza" post="cases over six seasonsEpidemiol Infect2018146779980810.1017/S095026881800066329606178 74.RodriguezADiazEMartin-LoechesIet al.Impact of early"/>
 <result pre="treatment on outcome in critically ill patients with 2009 pandemic" exact="influenza" post="AJ Antimicrob Chemother20116651140114910.1093/jac/dkq51121385717 75.DollMKWintersNBoikosCKraicer-MelamedHGoreGQuachCSafety and effectiveness of neuraminidase inhibitors"/>
 <result pre="AJ Antimicrob Chemother20116651140114910.1093/jac/dkq51121385717 75.DollMKWintersNBoikosCKraicer-MelamedHGoreGQuachCSafety and effectiveness of neuraminidase inhibitors for" exact="influenza" post="treatment, prophylaxis, and outbreak control: a systematic review of"/>
 <result pre="77.LouieJKYangSAcostaMet al.Treatment with neuraminidase inhibitors for critically ill patients with" exact="influenza" post="A (H1N1)pdm09Clin Infect Dis20125591198120410.1093/cid/cis63622843781 78.Lytras T, Mouratidou E, Andreopoulou"/>
 <result pre="intervention study on higher-dose oseltamivir treatment in adults hospitalized with" exact="influenza" post="a and B infectionsClin Infect Dis201357111511151910.1093/cid/cit59724046309 89.NoelZRBastinMLTMontgomeryAAFlanneryAHComparison of high-dose"/>
 <result pre="randomized study of standard versus double dose oseltamivir for treating" exact="influenza" post="in the communityAntivir Ther201520768969810.3851/IMP280724912485 93.PaiMPLodiseTPJrOseltamivir and oseltamivir carboxylate pharmacokinetics"/>
 <result pre="is not necessaryAntimicrob Agents Chemother201155125640564510.1128/AAC.00422-1121930881 94.Thorne-HumphreyLMGoralskiKBSlayterKLet al.Oseltamivir pharmacokinetics in morbid" exact="obesity" post="(OPTIMO trial)J Antimicrob Chemother20116692083209110.1093/jac/dkr25721700623 95.collab: To KKHungIFLiIWet al.Delayed clearance"/>
 <result pre="marked cytokine activation in severe cases of pandemic H1N1 2009" exact="influenza" post="virus infectionClin Infect Dis201050685085910.1086/65058120136415 96.LeeNChanPKWongCKet al.Viral clearance and inflammatory"/>
 <result pre="and inflammatory response patterns in adults hospitalized for pandemic 2009" exact="influenza" post="A(H1N1) virus pneumoniaAntivir Ther201116223724710.3851/IMP172221447873 97.IsonMGde JongMDGilliganKJet al.End points for"/>
 <result pre="A(H1N1) virus pneumoniaAntivir Ther201116223724710.3851/IMP172221447873 97.IsonMGde JongMDGilliganKJet al.End points for testing" exact="influenza" post="antiviral treatments for patients at high risk of severe"/>
 <result pre="two placebo-controlled trialsAntivir Ther201520770971910.3851/IMP287425318121 100.IsonMGFraizJHellerBet al.Intravenous peramivir for treatment of" exact="influenza" post="in hospitalized patientsAntivir Ther201419434936110.3851/IMP268023985625 101.LeeJParkJHJwaHKimYHComparison of efficacy of intravenous"/>
 <result pre="peramivir compared with oral oseltamivir for the treatment of seasonal" exact="influenza" post="in hospitalized adultsAntivir Ther201318565166110.3851/IMP244223111657 103.de JongMDIsonMGMontoASet al.Evaluation of intravenous"/>
 <result pre="Ther201318565166110.3851/IMP244223111657 103.de JongMDIsonMGMontoASet al.Evaluation of intravenous peramivir for treatment of" exact="influenza" post="in hospitalized patientsClin Infect Dis20145912e172e18510.1093/cid/ciu63225115871 104.NakamuraSMiyazakiTIzumikawaKet al.Efficacy and safety"/>
 <result pre="intravenous peramivir compared with oseltamivir in high-risk patients infected with" exact="influenza" post="A and B viruses: a multicenter randomized controlled studyOpen"/>
 <result pre="controlled studyOpen Forum Infect Dis201743ofx12910.1093/ofid/ofx12928761899 105.HaydenFGSugayaNHirotsuNet al.Baloxavir marboxil for uncomplicated" exact="influenza" post="in adults and adolescentsN Engl J Med20183791091392310.1056/NEJMoa171619730184455 106.OmotoSSperanziniVHashimotoTet al.Characterization"/>
 <result pre="in adults and adolescentsN Engl J Med20183791091392310.1056/NEJMoa171619730184455 106.OmotoSSperanziniVHashimotoTet al.Characterization of" exact="influenza" post="virus variants induced by treatment with the endonuclease inhibitor"/>
 <result pre="a randomized trial for pandemic critical illness: the 2009 H1N1" exact="influenza" post="pandemicIntensive Care Med2012381293910.1007/s00134-011-2409-822120766 109.HanKMaHAnXet al.Early use of glucocorticoids was"/>
 <result pre="Dis201153432633310.1093/cid/cir39821810744 110.MorenoGRodriguezAReyesLFet al.Corticosteroid treatment in critically ill patients with severe" exact="influenza" post="pneumonia: a propensity score matching studyIntensive Care Med20184491470148210.1007/s00134-018-5332-430074052 111.RodrigoCLeonardi-BeeJNguyen-Van-TamJSLimWSEffect"/>
 <result pre="Dis2015212218319410.1093/infdis/jiu64525406333 112.YangJWFanLCMiaoXYet al.Corticosteroids for the treatment of human infection with" exact="influenza" post="virus: a systematic review and meta-analysisClin Microbiol Infect2015211095696310.1016/j.cmi.2015.06.02226123860 113.NiYNChenGSunJLiangBMLiangZAThe"/>
 <result pre="Infect2015211095696310.1016/j.cmi.2015.06.02226123860 113.NiYNChenGSunJLiangBMLiangZAThe effect of corticosteroids on mortality of patients with" exact="influenza" post="pneumonia: a systematic review and meta-analysisCrit Care20192319910.1186/s13054-019-2395-830917856 114.Brun-BuissonCRichardJCMercatAThiebautACBrochardLcollab: Group"/>
 <result pre="review and meta-analysisCrit Care20192319910.1186/s13054-019-2395-830917856 114.Brun-BuissonCRichardJCMercatAThiebautACBrochardLcollab: Group R-SAHNvREarly corticosteroids in severe" exact="influenza" post="a/H1N1 pneumonia and acute respiratory distress syndromeAm J Respir"/>
 <result pre="meta-analysisCrit Care20192319910.1186/s13054-019-2395-830917856 114.Brun-BuissonCRichardJCMercatAThiebautACBrochardLcollab: Group R-SAHNvREarly corticosteroids in severe influenza a/H1N1" exact="pneumonia" post="and acute respiratory distress syndromeAm J Respir Crit Care"/>
 <result pre="Med201118391200120610.1164/rccm.201101-0135OC21471082 115.KimSHHongSBYunSCet al.Corticosteroid treatment in critically ill patients with pandemic" exact="influenza" post="A/H1N1 2009 infection: analytic strategy using propensity scoresAm J"/>
 <result pre="Database Syst Rev20192CD01040630798570 117.LeeNCockramCSChanPKHuiDSChoiKWSungJJAntiviral treatment for patients hospitalized with severe" exact="influenza" post="infection may affect clinical outcomesClin Infect Dis20084681323132410.1086/53347718444878 118.GiannellaMAlonsoMGarcia de"/>
 <result pre="Infect Dis20084681323132410.1086/53347718444878 118.GiannellaMAlonsoMGarcia de ViedmaDet al.Prolonged viral shedding in pandemic" exact="influenza" post="a(H1N1): clinical significance and viral load analysis in hospitalized"/>
 <result pre="120.WangYGuoQYanZet al.Factors associated with prolonged viral shedding in patients with" exact="avian influenza" post="A(H7N9) virus infectionJ Infect Dis2018217111708171710.1093/infdis/jiy11529648602 121.LeeNLeoYSCaoBet al.Neuraminidase inhibitors, superinfection"/>
 <result pre="al.Factors associated with prolonged viral shedding in patients with avian" exact="influenza" post="A(H7N9) virus infectionJ Infect Dis2018217111708171710.1093/infdis/jiy11529648602 121.LeeNLeoYSCaoBet al.Neuraminidase inhibitors, superinfection"/>
 <result pre="Dis2018217111708171710.1093/infdis/jiy11529648602 121.LeeNLeoYSCaoBet al.Neuraminidase inhibitors, superinfection and corticosteroids affect survival of" exact="influenza" post="patientsEur Respir J20154561642165210.1183/09031936.0016971425573405 122.Martin-LoechesILisboaTRhodesAet al.Use of early corticosteroid therapy"/>
 <result pre="on ICU admission in patients affected by severe pandemic (H1N1)v" exact="influenza" post="A infectionIntensive Care Med201137227228310.1007/s00134-010-2078-z21107529 123.DelaneyJWPintoRLongJet al.The influence of corticosteroid"/>
 <result pre="123.DelaneyJWPintoRLongJet al.The influence of corticosteroid treatment on the outcome of" exact="influenza" post="A(H1N1pdm09)-related critical illnessCrit Care2016207510.1186/s13054-016-1230-827036638 124.CaoBGaoHZhouBet al.Adjuvant corticosteroid treatment in"/>
 <result pre="critical illnessCrit Care2016207510.1186/s13054-016-1230-827036638 124.CaoBGaoHZhouBet al.Adjuvant corticosteroid treatment in adults with" exact="influenza" post="A (H7N9) viral pneumoniaCrit Care Med2016446e318e32810.1097/CCM.000000000000161626934144 125.BeigelJHBaoYBeelerJet al.Oseltamivir, amantadine,"/>
 <result pre="Dis201717121255126510.1016/S1473-3099(17)30476-028958678 126.SeoSEnglundJANguyenJTet al.Combination therapy with amantadine, oseltamivir and ribavirin for" exact="influenza" post="A infection: safety and pharmacokineticsAntivir Ther201318337738610.3851/IMP247523264438 127.KimWYYoung SuhGHuhJWet al.Triple-combination"/>
 <result pre="pharmacokineticsAntivir Ther201318337738610.3851/IMP247523264438 127.KimWYYoung SuhGHuhJWet al.Triple-combination antiviral drug for pandemic H1N1" exact="influenza" post="virus infection in critically ill patients on mechanical ventilationAntimicrob"/>
 <result pre="efficacy and safety study of favipiravir for treatment of uncomplicated" exact="influenza" post="in adults - T705US316. ClinicalTrialsgov [Internet]. November 11, 2015"/>
 <result pre="Oseltamivir (Tamiflu®) compared with Oseltamivir alone in hospitalized adults with" exact="influenza" post="a infection requiring oxygen support. ClinicalTrialsgov [internet]. August 28,"/>
 <result pre="in combination with oseltamivir versus oseltamivir in participants with severe" exact="influenza" post="a infection. ClinicalTrialsgov [internet]. June 18, 2018 ed2018BethesdaNational Library"/>
 <result pre="al.Convalescent plasma treatment reduced mortality in patients with severe pandemic" exact="influenza" post="A (H1N1) 2009 virus infectionClin Infect Dis201152444745610.1093/cid/ciq10621248066 136.HungIFNcollab: To"/>
 <result pre="multicenter double-blind randomized controlled trial for patients with severe 2009" exact="influenza" post="A(H1N1) infectionChest2013144246447310.1378/chest.12-290723450336 137.HungIA randomized controlled trial on the treatment"/>
 <result pre="infectionChest2013144246447310.1378/chest.12-290723450336 137.HungIA randomized controlled trial on the treatment of severe" exact="influenza" post="a infection. ClinicalTrialsgov [internet]. July 25, 2017 ed2017BethesdaNational Library"/>
</results>
